The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10148 malaria professionals are enjoying the free benefits of MalariaWorld today

dihydroartemisinin

NOT Open Access | Baseline Ex Vivo and Molecular Responses of Plasmodium falciparum Isolates to Piperaquine before Implementation of Dihydroartemisinin-Piperaquine in Senegal

April 30, 2019 - 15:21 -- NOT Open Access
Author(s): 
Marie Gladys Robert, Francis Foguim Tsombeng, Mathieu Gendrot, Silman Diawara, Marylin Madamet, Mame Bou Kounta, Khalifa Ababacar Wade, Mansour Fall, Mamadou Wague Gueye, Nicolas Benoit, Aminata Nakoulima, Raymond Bercion, Rémy Amalvict, Bécaye Fall, Boubacar Wade, Bakary Diatta and Bruno Pradines
Reference: 
Antimicrob. Agents Chemother. April 2019 63:e02445-18

Dihydroartemisinin-piperaquine, which was registered in 2017 in Senegal, is not currently used as the first-line treatment against uncomplicated malaria. A total of 6.6% to 17.1% of P. falciparum isolates collected in Dakar in 2013 to 2015 showed ex vivo-reduced susceptibility to piperaquine. 

Country: 
Medical Treatment: 

In Vitro Sensitivity of Plasmodium falciparum from China-Myanmar Border Area to Major ACT Drugs and Polymorphisms in Potential Target Genes

June 14, 2012 - 07:59 -- Kabogo Ndegwa
Author(s): 
Zenglei Wang, Daniel Parker, Zhaoqing Yang, et al.
Reference: 
PLoS ONE 7(5): e30927

MalariaWorldDrug resistance has always been one of the most important impediments to global malaria control.

Country: 
Medical Condition: 

NOT Open Access | Proveblue (Methylene Blue) as an Antimalarial Agent: In Vitro Synergy with Dihydroartemisinin and Atorvastatin

May 16, 2012 - 06:30 -- Kabogo Ndegwa
Author(s): 
Jérôme Dormoi, Aurélie Pascual, Sébastien Briolant, Rémy Amalvict, Serge Charras, Eric Baret, Emilie Huyghues des Etages, Michel Feraud, and Bruno Pradines
Reference: 
Antimicrob. Agents Chemother. June 2012 vol. 56 no. 6 3467-3469

MalariaWorldProveblue (international patent no PCT/FR/2007/001193), which is a methylene blue preparation that complies with the European Pharmacopoeia and contains limited organic impurities and heavy metals of recognized toxicity, has previously been demonstrated to possess in vitro antimalarial activity (at a geometric mean IC50s of 3.62 nM) against 23 Plasmodium falciparum strains that are resistant to various other antimalarials (11).…

Medical Condition: 

Open Access | Artemether resistance in vitro is linked to mutations in PfATP6 that also interact with mutations in PfMDR1 in travellers returning with Plasmodium falciparum infections

May 2, 2012 - 14:27 -- Kabogo Ndegwa
Author(s): 
Pillai DR, Lau R, Khairnar K, Lepore R, Via A, Staines HM, Krishna S
Reference: 
Malaria Journal 2012, 11:131 (27 April 2012)

MalariaWorldThese findings were further explored in molecular modelling experiments that suggest mutations in pfatp6 are unlikely to affect differential binding of artemisinins at their proposed site, whereas there may be differences in such binding associated with mutations in pfmdr1.

Open Access | Population Pharmacokinetics of Dihydroartemisinin and Piperaquine in Pregnant and Nonpregnant Women with Uncomplicated Malaria

March 22, 2012 - 06:47 -- Kabogo Ndegwa
Author(s): 
Joel Tarning, Marcus J. Rijken, Rose McGready, Aung Pyae Phyo, Warunee Hanpithakpong, Nicholas P. J. Day, Nicholas J. White, François Nosten, and Niklas Lindegardh
Reference: 
Antimicrob. Agents Chemother. April 2012 vol. 56 no. 4 1997-2007

MalariaWorldPregnant women are particularly vulnerable to malaria. The pharmacokinetic properties of antimalarial drugs are often affected by pregnancy, resulting in lower drug concentrations and a consequently higher risk of treatment failure.

Medical Condition: 
Medical Treatment: 

Open Access | Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration

September 21, 2011 - 13:14 -- Kabogo Ndegwa
Author(s): 
Carrie A Morris, Stephan Duparc, Isabelle Borghini-Fuhrer, Donald Jung, Chang-Sik Shin, Lawrence Fleckenstein
Reference: 
Malaria Journal 2011, 10:263 (13 September 2011)

Artesunate (AS) is a clinically versatile artemisinin derivative utilized for the treatment of mild to severe malaria infection.

Medical Condition: 
Medical Treatment: 

Antiplasmodial and antitumor activity of dihydroartemisinin analogs derived via the aza-Michael addition reaction

May 4, 2011 - 12:43 -- Kabogo Ndegwa
Author(s): 
Tzu-Shean Feng, Eric M. Guantai, Margo J. Nell, Constance E.J. van Rensburg, Heinrich C. Hoppe, Kelly Chibale
Reference: 
Bioorganic & Medicinal Chemistry Letters, Volume 21, Issue 10, 15 May 2011, Pages 2882-2886

A series of dihydroartemisinin derivatives were synthesized via an aza-Michael addition reaction to a dihydroartemisinin-based acrylate and were evaluated for antiplasmodial and antitumor activity.

Selective toxicity of dihydroartemisinin on human CD34+ erythroid cell differentiation

September 14, 2010 - 13:03 -- Patrick Sampao
Author(s): 
Sara Finaurini, Luisa Ronzoni, Alessandra Colancecco, Alessandra Cattaneo, Maria Domenica Cappellini, Stephen A. Ward, Donatella Taramelli
Reference: 
Toxicology, Volume 276, Issue 2, 9 October 2010, Pages 128-134

This is the first demonstration that DHA affects human erythropoiesis in vitro, in a dose- and time-dependent manner; the target population seems to be the pro-erythroblast and basophilic erythroblast stage, suggesting that DHA toxicity is limited to primitive human erythropoiesis.

Medical Condition: 

Open Access | Commentary: The pharmaceutical death-ride of dihydroartemisinin

July 26, 2010 - 14:23 -- Kabogo Ndegwa
Author(s): 
Jansen F
Reference: 
Malaria Journal 2010, 9:212 (22 July 2010)

In the 2010 second edition of WHO's guidelines for the treatment of malaria, the relatively new fixed dose combination dihydroartemisinin-piperaquine is included as one of the recommended artemisinin combination therapies.

Product: 

Orally active esters of dihydroartemisinin: Synthesis and antimalarial activity against multidrug-resistant Plasmodium yoelii in mice

February 13, 2010 - 11:42 -- Kabogo Ndegwa
Author(s): 
Chandan Singh, Sandeep Chaudhary and Sunil K. Puri
Reference: 
Bioorganic & Medicinal Chemistry Letters, Volume 18, Issue 4, 15 February 2008, Pages 1436-1441

A series of artemisinin derived esters 7a–j, incorporating pharmacologically privileged substructure, such as biphenyl, adamantane and fluorene, have been prepared and evaluated for antimalarial activity against multidrug-resistant (MDR) Plasmodium yoelii nigeriensis by oral route.

Medical Condition: 

Pages

Subscribe to RSS - dihydroartemisinin